In this study, we reported that cimifugin significantly inhibited the expressions of TSLP and IL‐33 in the initial stage of AD model and the results were validated in vitro, which indicated that regulating TSLP and IL‐33 might be the underlying mechanism of cimifugin. This evidence concerns the gene IL33 and Alzheimer disease.